The number that should stop every healthcare administrator

At any given moment in U.S. hospitals, approximately 1 in every 31 inpatients has a healthcare-associated infection. That figure — published by the CDC in its January 2026 National HAI Progress Report — represents not a historical average or a worst-case projection. It represents today. It represents the patient in the bed three rooms down. It represents the surgical patient recovering in the unit upstairs. It represents a preventable harm that is occurring at scale, every day, in every acute care hospital in the United States.

The financial dimension is equally stark. CDC estimates that HAIs result in approximately 722,000 infections and 75,000 deaths in U.S. hospitals annually, generating $28–33 billion in direct excess costs. When calculated against the Consumer Price Index for inpatient hospital services, that range extends to $35.7–$45 billion. Per-case costs for the five most common HAIs range from $896 per catheter-associated urinary tract infection to $45,814 per central-line bloodstream infection.

What the CDC’s January 2026 data actually shows

The 2024 National HAI Progress Report (published January 2026) tracks HAI rates across four healthcare settings using Standardized Infection Ratios (SIR): acute care hospitals, critical access hospitals, inpatient rehabilitation facilities, and long-term acute care hospitals.

The progress is real in some areas. Between 2023 and 2024, acute care hospitals saw significant reductions in C. difficile infection (11% decrease), catheter-associated urinary tract infections (10%), central-line bloodstream infections (9%), MRSA (7%), surgical site infections following colon surgery (4%), and ventilator-associated events (2%). These are meaningful reductions achieved through sustained attention to hand hygiene, device care bundles, and surface disinfection protocols.

The five most costly HAIs — and what drives each

What the $28–45 billion figure actually means for a hospital administrator

The national aggregate is useful for context. The institutional calculation is where it becomes actionable. A 300-bed acute care hospital with a 5% HAI rate and average occupancy sees roughly 4,000–5,000 patient admissions per year, generating 200–250 HAI events annually. At an average cost of $10,000–$15,000 per HAI event (blending the five major categories), that represents $2–3.75 million in excess costs per year — before accounting for litigation exposure, reputational damage, CMS reimbursement penalties, and the value-based care adjustments that are increasingly tied to HAI rates.

The CMS Hospital-Acquired Condition Reduction Program penalizes hospitals in the worst-performing quartile on HAI measures with a 1% reduction in Medicare payments — a meaningful financial consequence for large institutions. Value-based care contracts increasingly tie reimbursement to quality outcomes, of which HAI rates are a primary metric. The institutional calculus on infection prevention investment is not ambiguous: the cost of prevention is a fraction of the cost of the infection.

What the right surface disinfection standard looks like

HAIs are caused by a combination of factors: hand hygiene failures, device care gaps, antibiotic selection pressure, and environmental surface contamination. Surface disinfection is the one factor that is most directly addressable through product selection and protocol design. The research is clear on what effective environmental disinfection requires: an EPA-registered product with validated kill claims for the relevant pathogens, applied to pre-cleaned surfaces, held wet for the required contact time.